中西医结合心血管病电子杂志
中西醫結閤心血管病電子雜誌
중서의결합심혈관병전자잡지
Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine (Electronic)
2014年
9期
5-6
,共2页
冠状动脉粥样硬化性心脏病%心绞痛%通心络胶囊%倍他乐克
冠狀動脈粥樣硬化性心髒病%心絞痛%通心絡膠囊%倍他樂剋
관상동맥죽양경화성심장병%심교통%통심락효낭%배타악극
Coronary heart disease%angina%Tongxinluo capsule%Betaloc
目的：分析和研究冠状动脉粥样硬化性心脏病（简称冠心病）心绞痛采用通心络胶囊与倍他乐克联合治疗的临床效果。方法选取2013年1月～2014年4月冠心病心绞痛患者94例，将其按数字随机表法分为观察组47例与对照组47例。对照组患者给予倍他乐克治疗；观察组患者在对照组治疗基础上加用通心络胶囊治疗，将两组患者治疗4周后的疗效及不良反应发生情况进行比较。结果两组患者疗效相比较：观察组高于对照组（P＜0.05）。两组患者治疗期间不良反应发生率相比较无明显差异（P＞0.05）。结论将通心络胶囊与倍他乐克联合应用于冠心病心绞痛患者治疗中，能够有效改善患者心功能，降低心肌耗氧量，并且患者在治疗期间不良反应症状较轻微，安全可靠，对提高治疗效果及改善患者预后均有重要作用。
目的：分析和研究冠狀動脈粥樣硬化性心髒病（簡稱冠心病）心絞痛採用通心絡膠囊與倍他樂剋聯閤治療的臨床效果。方法選取2013年1月～2014年4月冠心病心絞痛患者94例，將其按數字隨機錶法分為觀察組47例與對照組47例。對照組患者給予倍他樂剋治療；觀察組患者在對照組治療基礎上加用通心絡膠囊治療，將兩組患者治療4週後的療效及不良反應髮生情況進行比較。結果兩組患者療效相比較：觀察組高于對照組（P＜0.05）。兩組患者治療期間不良反應髮生率相比較無明顯差異（P＞0.05）。結論將通心絡膠囊與倍他樂剋聯閤應用于冠心病心絞痛患者治療中，能夠有效改善患者心功能，降低心肌耗氧量，併且患者在治療期間不良反應癥狀較輕微，安全可靠，對提高治療效果及改善患者預後均有重要作用。
목적：분석화연구관상동맥죽양경화성심장병（간칭관심병）심교통채용통심락효낭여배타악극연합치료적림상효과。방법선취2013년1월～2014년4월관심병심교통환자94례，장기안수자수궤표법분위관찰조47례여대조조47례。대조조환자급여배타악극치료；관찰조환자재대조조치료기출상가용통심락효낭치료，장량조환자치료4주후적료효급불량반응발생정황진행비교。결과량조환자료효상비교：관찰조고우대조조（P＜0.05）。량조환자치료기간불량반응발생솔상비교무명현차이（P＞0.05）。결론장통심락효낭여배타악극연합응용우관심병심교통환자치료중，능구유효개선환자심공능，강저심기모양량，병차환자재치료기간불량반응증상교경미，안전가고，대제고치료효과급개선환자예후균유중요작용。
Objective Analysis and Study on angina pectoris of coronary heart disease with the clinicaleffect of Tongxinluo capsule combined with betaloc treatment. Method From 2013 January to 2014 April, 94 patients with angina pectoris, according to itsdigital randomly divided into the observation group 47 cases and control group of 47 cases. Patients in control group were treated with betaloc in the treatment; the observation group patients treated in the control group treated with Tongxinluo capsule, two patients in treatment group curative effect and adverse reaction of 4 weeks after the occurrence of comparison. Result The treatment effect of the two groups of patients: comparison of observation groupwas higher than the control group P<0.05. Adverse reactions during treatment in the patients of two groups had no significant difference compare the incidence of P>0.05. Conclusion The Tongxinluo capsule combined with betaloc applied in treatment of patients withangina pectoris of coronary heart disease patients, can obviously improve heart function, reduce myocardial oxygen consumption, and during the treatment in patients with adverse reactions were mild, safe and reliable, and improve the treatment effect of patients with pre have important role.
